EGFR and lung adenocarcinoma: With evidence that molecular targeted therapy is a major improvement over conventional chemotherapy when applied to appropriately selected patients, the evaluation for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements are considered to be the standard of care in advanced lung adenocarcinomas [2].